Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ANI Pharmaceuticals, Inc. reported revenue of $883M, up 43.8% year over year. Operating margin was 12.6% and net margin 8.9%, on a free-cash-flow margin of 19.4% with capital expenditure at 1.6% of revenue. Every figure is computed directly from ANIP's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $883M | 12.6% | 8.9% |
| FY2024 | $614M | 0.1% | -3.0% |
| FY2023 | $487M | 9.6% | 3.9% |
| FY2022 | $316M | -11.2% | -15.1% |
| FY2021 | $216M | -18.4% | -19.7% |
How does ANIP compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.